Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :28784429
Publication Date : 2017/08/08

Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.


Leukotrienes are proinflammatory lipid mediators associated with diverse chronic inflammatory diseases such as asthma, COPD, IBD, arthritis, atherosclerosis, dermatitis and cancer. Cellular leukotrienes are produced from arachidonic acid via the 5-lipoxygenase pathway in which the 5-lipoxygenase activating protein, also named as FLAP, plays a critical role by operating as a regulatory protein for efficient transfer of arachidonic acid to 5-lipoxygenase. By blocking leukotriene production, FLAP inhibitors may behave as broad-spectrum leukotriene modulators, which might be of therapeutic use for chronic inflammatory diseases requiring anti-leukotriene therapy. The early development of FLAP inhibitors (i.e. MK-886, MK-591, BAY-X-1005) mostly concentrated on asthma cure, and resulted in promising readouts in preclinical and clinical studies with asthma patients. Following the recent elucidation of the 3D-structure of FLAP, development of new inhibitor chemotypes is highly accelerated, eventually leading to the evolution of many un-drug-like structures into more drug-like entities such as AZD6642 and BI665915 as development candidates. The most clinically advanced FLAP inhibitor to date is GSK2190918 (formerly AM803) that has successfully completed phase II clinical trials in asthmatics. Concluding, although there are no FLAP inhibitors reached to the drug approval phase yet, due to the rising number of indications for anti-LT therapy such as atherosclerosis, FLAP inhibitor development remains a significant research field. FLAP inhibitors reviewed herein are classified into four sub-classes as the first-generation FLAP inhibitors (indole and quinoline derivatives), the second-generation FLAP inhibitors (diaryl-alkanes and biaryl amino-heteroarenes), the benzimidazole-containing FLAP inhibitors and other FLAP inhibitors with polypharmacology for easiness of the reader. Hence, we meticulously summarize how FLAP inhibitors historically developed from scratch to their current advanced state, and leave the reader with a positive view that a FLAP inhibitor might soon reach to the need of patients who may require anti-LT therapy.

Authors : Gür Zehra Tuğçe , Çalışkan Burcu , Banoglu Erden ,

Related products :

Catalog number Product name Quantity
PLDS-PLD Peptoid Ligand Discovery Drug Discovery Service Peptoid Ligand Screening
28-734 AIP may play a positive role in AHR-mediated signalling possibly by influencing its receptivity for ligand and_or its nuclear targeting. AIP is the cellular negative regulator of the HBV X protein. 0.1 mg
28-634 AIP may play a positive role in AHR-mediated signalling possibly by influencing its receptivity for ligand and_or its nuclear targeting. AIP is the cellular negative regulator of the HBV X protein. 0.1 mg
28-333 AIP may play a positive role in AHR-mediated signalling possibly by influencing its receptivity for ligand and_or its nuclear targeting. AIP is the cellular negative regulator of the HBV X protein.AIP 0.1 mg
ER955 5-Lipoxygenase Activating Protein Elisa Kit 96T
E10001h Human Five Lipoxygenase Activating Protein ELISA K 96T
PLDS-ADPL Peptoid Ligand Assay Development Drug Discovery Service Peptoid Ligand Screening
PLDS-PLAO Peptoid Ligand Affinity Optimization Drug Discovery Service Peptoid Ligand Screening
PLDS-SPLS Single Peptoid Ligand Synthesis Drug Discovery Service Peptoid Synthesis
CSB-EL001625RA Rat Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit 96T
ALPI ALOX5AP Gene arachidonate 5-lipoxygenase-activating protein
CSB-EL001625BO Bovine Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit 96T
CSB-EL001625HU Human Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit 96T
CSB-EL001625MO Mouse Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit 96T
CSB-EL001625HO Horse Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit 96T
bs-7556R Rabbit Anti-5-lipoxygenase activating protein Polyclonal Antibody 100ul
CSB-EL001625RA Rat Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit SpeciesRat 96T
CSB-EL001625PI Pig Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit SpeciesPig 96T
PLDS-PLS Peptoid Library Synthesis Drug Discovery Service Peptoid Synthesis
CSB-EL001625BO Bovine Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit SpeciesBovine 96T
bs-7556R Rabbit Anti-FLAP_5-lipoxygenase activating protein Polyclonal Antibody 100ug Lyophilized
bs-7556R-Cy5 Rabbit Anti-5-lipoxygenase activating protein Polyclonal Antibody, Cy5 Conjugated 100ul
CSB-EL001625RB Rabbit Arachidonate 5-lipoxygenase-activating protein(ALOX5AP) ELISA kit SpeciesRabbit 96T
bs-7556R-Cy5.5 Rabbit Anti-5-lipoxygenase activating protein Polyclonal Antibody, Cy5.5 Conjugated 100ul
bs-7556R-Cy7 Rabbit Anti-5-lipoxygenase activating protein Polyclonal Antibody, Cy7 Conjugated 100ul


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur